GSK raises bet on AIDS drug with new Shionogi deal 
October 29th, 2012
Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. GlaxoSmithKline announce their half yearly results on Wednesday July 23. Credit: Reuters/Toby Melville By Ben Hirschler and Mayumi Negishi LONDON/TOKYO | Mon Oct 29, 2012 7:03am EDT LONDON/TOKYO (Reuters) – GlaxoSmithKline has raised its bet on a promising drug for HIV/AIDS by redrawing a deal with Japan’s Shionogi which gives it a much bigger economic interest in the new product
[Continue Reading...]
UCB’s next generation drugs take over after blockbuster expiry
October 29th, 2012
BRUSSELS | Mon Oct 29, 2012 2:39am EDT BRUSSELS (Reuters) – Belgian pharmaceuticals group UCB said on Monday that sales of its three new main products had for the first time overtaken those of its expiring blockbuster epilepsy treatment Keppra and retained its full-year guidance. UCB, which makes drugs targeted at diseases of the immune and central nervous systems, said on Monday sales of Cimzia, Neupro and Vimpat rose 50 percent to 665 million euros over the first nine months and were now treating about 382,000 patients.
[Continue Reading...]
Intuitive Surgical procedure growth disappoints
October 16th, 2012
By Bill Berkrot Tue Oct 16, 2012 6:57pm EDT (Reuters) – Intuitive Surgical Inc on Tuesday lowered its full-year forecast for procedure growth after posting a disappointing growth rate of 22 percent for surgeries using its high-priced da Vinci robots in the third quarter.
[Continue Reading...]
FDA approves Celgene’s Abraxane for lung cancer
October 12th, 2012
Fri Oct 12, 2012 10:16am EDT (Reuters) – U.S. health regulators on Friday widened the approved use of Celgene Corp’s breast cancer drug Abraxane to include treatment for non-small cell lung cancer, the most common form of lung cancer.
[Continue Reading...]
Nobel laureate Yamanaka warns of rogue "stemcell therapies"
October 9th, 2012
Tweet Share this Email Print Kyoto University Professor Shinya Yamanaka talks with Japan’s Prime Minister Yoshihiko Nada by a mobile phone during a news conference in Kyoto, western Japan, in this photo taken by Kyodo October 8, 2012. Credit: Reuters/Kyodo By Tan Ee Lyn HONG KONG | Tue Oct 9, 2012 7:41am EDT HONG KONG (Reuters) – Nobel laureate Shinya Yamanaka warned patients on Tuesday about unproven “stem cell therapies” offered at clinics and hospitals in a growing number of countries, saying they were highly risky.
[Continue Reading...]
Analysis: Reprogrammed cells open new medical window
October 8th, 2012
1 of 3. This undated handout photo shows iPS cells derived from adult human dermal fibroblasts released by Kyoto University Professor Shinya Yamanaka at Center for iPS Cell Research and Application of Kyoto University in Kyoto, western Japan.
[Continue Reading...]
UK, Japan scientists win Nobel for stem cell breakthroughs
October 8th, 2012
1 of 7. Kyoto University Professor Shinya Yamanaka (L) and John Gurdon of the Gurdon Institute in Cambridge are seen at a symposium on induced pluripotent stem cell in Tokyo, in this photo taken by Kyodo on April 2008.
[Continue Reading...]
Canadian health regulators approve InterMune’s fibrosis drug
October 2nd, 2012
Tue Oct 2, 2012 6:08pm EDT (Reuters) – Biotechnology company InterMune Inc said Canadian health regulators approved its drug to treat idiopathic pulmonary fibrosis, a fatal lung disease.
[Continue Reading...]
ArQule, Daiichi Sankyo discontinue lung cancer drug trial
October 2nd, 2012
Tue Oct 2, 2012 9:24am EDT (Reuters) – Biotechnology company ArQule Inc and Japan’s Daiichi Sankyo Co Ltd said they will discontinue a late-stage trial of their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival.
[Continue Reading...]
Spike in heart failures follows Japan’s 2011 quake
September 27th, 2012
By Kerry Grens NEW YORK | Thu Sep 27, 2012 12:50pm EDT NEW YORK (Reuters Health) – Following the massive earthquake and tsunami of March, 2011, which devastated parts of eastern Japan, the number of heart failure cases spiked in Miyagi Prefecture and remained elevated for six weeks, according to a new study.
[Continue Reading...]
